Pemetrexed & Gemcitabine

DRUG2 trials

Sponsors

Duke University, Swiss Cancer Institute

Conditions

Metastatic NSCLC - Non-Small Cell Lung CancerNon Small Cell Lung Cancer

Phase 2

Study Using a Genomic Predictor of Platinum Resistance to Guide Therapy in Stage IIIB/IV Non-Small Cell Lung Cancer

TerminatedNCT00509366

Duke UniversityNon Small Cell Lung Cancer

Start: 2007-05-31End: 2011-12-31Updated: 2014-08-28

Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%

RecruitingNCT07020065

Swiss Cancer InstituteMetastatic NSCLC - Non-Small Cell Lung Cancer

Start: 2026-04-10End: 2030-09-01Target: 156Updated: 2026-04-15